Encoded Therapeutics Receives Approval for Dravet Syndrome Treatment Research

Encoded Therapeutics’ research application for its Dravet Syndrome treatment prospect has been approved by the Medicines and Health Products Regulatory Agency.  

The early-stage trial is set to evaluate the candidate’s risks and tolerability and deduce the optimum dosage.  

Encoded’s drug treatment is a one-time, disease-altering gene control prospect targeting the root cause of Dravet syndrome. 

Dravet syndrome is a rare, severe form of epilepsy characterized by prolonged seizures, developmental delays, and cognitive impairment, often caused by mutations in the SCN1A gene.  

Sal Rico, the head medical chief at Encoded, stated, “We believe ETX101 has the potential to deliver transformative benefit in multiple disease domains and have designed our clinical programme to efficiently assess its impact on affected infants and young children.”  

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.